Drugs / CD33 FPBMC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07270978 | Mar 2026 → Aug 2028 expected | acute myeloid leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm | University of Virginia | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD33 FPBMC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07270978 ↗ |
| Known as | CD33Bi FPBMC | “combining anti-CD3 x anti-CD33 bispecific antibody (CD33Bi) armed fresh peripheral blood mononuclear cells (CD33Bi FPBMC)” NCT07270978 ↗ |
| Action | Deplete | “so the T cells can multiply and kill AML/MDS cells.” NCT07270978 ↗ |
| Modality | Cell therapy | “armed fresh peripheral blood mononuclear cells” NCT07270978 ↗ |
| Route | Intravenous | “CD33 FPBMC by intravenous infusion” NCT07270978 ↗ |
| Target | CD33 | “anti-CD3 x anti-CD33 bispecific antibody” NCT07270978 ↗ |